Analyst Upgrades: Netflix, Cree, and Salix Pharma

Analysts upwardly revised their ratings on Netflix, Inc. (NFLX), Cree, Inc. (CREE), and Salix Pharmaceuticals, Ltd. (SLXP)

Jan 21, 2015 at 9:30 AM
facebook X logo linkedin


Analysts are weighing in today on streaming content provider Netflix, Inc. (NASDAQ:NFLX), LED specialist Cree, Inc. (NASDAQ:CREE), and drugmaker Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP). Here's a quick roundup of today's bullish brokerage notes on NFLX, CREE, and SLXP.

  • NFLX is up almost 19% ahead of the bell, after last night's earnings beat prompted a rush of bullish brokerage attention. Specifically, no fewer than 13 analysts upped their price targets -- the most ambitious of which came from J.P. Morgan Securities, which raised its target to $511 from $450, and reiterated an "overweight" rating. This is good news for recent options traders, who have displayed optimism over the last couple of weeks. On the technical front, a sharp move higher would represent a break from Netflix, Inc.'s prevailing technical pattern, as the shares have advanced just 2.1% year-to-date to trade at $348.80.

  • CREE also topped the Street's expectations during its trip to the earnings confessional last night, and is pointed 4.4% higher this morning. Adding fuel to the equity's fire is a pair of price-target hikes from Susquehanna (to $31) and J.P. Morgan Securities (to $39). Technically speaking, Cree, Inc. has been a long-term laggard, shedding 48.5% of its value year-over-year to rest at $32.34. Not surprisingly, bearish betting has been popular on the stock. Nearly 18% of CREE's float is sold short -- which would take more than two weeks to cover, at typical daily trading levels -- and the equity's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 1.10 ranks in the 82nd percentile of its annual range.

  • Mizuho boosted its price target on SLXP to $124 from $103 -- and reiterated its "neutral" rating -- after news that the pharmaceutical firm is allegedly exploring strategic options, including a possible sale. On the charts, the shares have performed admirably, tacking on 25.8% over the last year to trade at $125.83 -- including a 4.7% surge yesterday following the aforementioned report. Despite this technical tenacity, 18% of Salix Pharmaceuticals, Ltd.'s float is sold short, which represents nearly seven days' worth of pent-up buying power, at typical daily trading volumes. If the stock can muscle higher, a short-covering rally could result.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI